Arcellx, Inc. (ACLX)
NASDAQ: ACLX · Real-Time Price · USD
113.79
-0.09 (-0.08%)
At close: Feb 27, 2026, 4:00 PM EST
113.77
-0.02 (-0.02%)
After-hours: Feb 27, 2026, 4:53 PM EST
Arcellx Revenue
In the year 2025, Arcellx had annual revenue of $22.29M, down -79.35%. Arcellx had revenue of $1.65M in the quarter ending December 31, 2025, a decrease of -89.17%.
Revenue (ttm)
$22.29M
Revenue Growth
-79.35%
P/S Ratio
298.51
Revenue / Employee
$136,724
Employees
163
Market Cap
6.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 22.29M | -85.65M | -79.35% |
| Dec 31, 2024 | 107.94M | -2.38M | -2.16% |
| Dec 31, 2023 | 110.32M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.73B |
| Caris Life Sciences | 812.03M |
| Rhythm Pharmaceuticals | 189.76M |
| Cytokinetics | 88.04M |
| Protagonist Therapeutics | 46.02M |
| Kymera Therapeutics | 39.21M |
| CRISPR Therapeutics AG | 3.51M |
ACLX News
- 4 days ago - Here's Why Shares of Arcellx Are Up Almost 80% Today - Investopedia
- 4 days ago - Why is Arcellx stock up 80% today? Gilead's $7.8B answer - Invezz
- 4 days ago - Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion - Reuters
- 4 days ago - Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion - WSJ
- 4 days ago - Gilead to acquire Arcellx for $7.8 billion - Reuters
- 4 days ago - Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel - Business Wire
- 4 days ago - Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel - Business Wire
- 23 days ago - Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel's D-Domain Binder - Business Wire